Zeller et al identified ARMCX2 as a primary target for acquired promoter DNA hypermethylation in cisplatin-resistant ovarian cancer cell lines, including cell lines derived from patients at relapse after becoming resistant to chemotherapy20. This evidence concerns the gene ARMCX2 and ovarian carcinoma.